Introduction to Ber-EP4 Expression in BCC

Clinicians widely use Ber-EP4 as a reliable immunohistochemical marker for diagnosing cutaneous basal cell carcinoma (BCC). This monoclonal antibody targets the epithelial cell adhesion molecule (EpCAM), which typically shows high levels of Ber-EP4 expression in BCC cells. While its sensitivity remains high, recent evidence suggests that staining distribution and intensity can vary. Consequently, understanding these variations is crucial for ensuring diagnostic accuracy, especially in small or fragmented skin biopsies.

Staining Patterns and Diagnostic Sensitivity

A recent clinicopathological study analyzed sixty cases of surgically excised BCC to evaluate Ber-EP4 staining patterns. Interestingly, every case in the cohort demonstrated Ber-EP4 positivity, confirming its role as a highly sensitive marker. The mean percentage of positive tumor cells reached approximately 78.1%. Furthermore, researchers observed high-level expression in over two-thirds of the cases. Although diffuse staining was the most common pattern, seen in 85% of tumors, 15% showed nondiffuse or focal staining. This variability highlights why pathologists must examine the entire tissue sample carefully to avoid false negatives.

The Impact of Ulceration on Ber-EP4 Expression in BCC

While Ber-EP4 expression in BCC is generally robust, certain clinicopathological features can influence results. Specifically, the presence of tumor ulceration significantly correlates with reduced marker expression. Statistical analysis showed that ulcerated tumors were twelve times more likely to exhibit lower Ber-EP4 levels. This finding is particularly relevant for superficially sampled lesions where the primary diagnostic area might be compromised by inflammation or necrosis. Therefore, clinicians should integrate histomorphological findings with immunohistochemistry rather than relying solely on a single marker.

Clinical Implications for Dermatopathology

The high sensitivity of Ber-EP4 makes it an excellent tool for differentiating BCC from other mimics, such as squamous cell carcinoma (SCC). However, the potential for reduced expression in specific contexts, such as ulcerated lesions, presents a diagnostic pitfall. Moreover, nondiffuse staining patterns require cautious interpretation. Pathologists should maintain a high index of suspicion when viewing squamoid features within a BCC, as these areas often show diminished staining. Ultimately, a combined approach ensures the most accurate diagnosis for patients undergoing skin cancer treatment.

Frequently Asked Questions

What is the role of Ber-EP4 in diagnosing skin cancer?

Ber-EP4 is a monoclonal antibody used in immunohistochemistry to identify EpCAM. It is highly sensitive for basal cell carcinoma and helps differentiate it from squamous cell carcinoma, which typically tests negative for this marker.

Can Ber-EP4 yield a negative result in a confirmed BCC?

While sensitivity is near 100%, expression can be reduced or focal, especially in ulcerated tumors or areas with squamoid differentiation. In such cases, the staining might appear weak or nondiffuse, requiring careful morphological correlation.

How does ulceration affect diagnostic markers in BCC?

Ulceration is associated with a significant reduction in the intensity and proportion of Ber-EP4-positive cells. This change can complicate the diagnosis if the biopsy sample is small or limited to the ulcerated area.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Tran GH et al. Ber-EP4 Expression and Staining Patterns in Cutaneous Basal Cell Carcinoma: A Clinicopathological Study From a Vietnamese Cohort. Am J Dermatopathol. 2026 Apr 07. doi: 10.1097/DAD.0000000000003287. PMID: 41945926.

2. Sellheyer K. The Use of BEREP4 Immunohistochemistry Staining for Detection of Basal Cell Carcinoma. NIH.gov. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791948/

3. Dasgeb B, Mohammadi TM, Mehregan DR. Use of Ber-EP4 and Epithelial Specific Antigen to Differentiate Clinical Simulators of Basal Cell Carcinoma. Biomark Cancer. 2013;5:7-11. doi: 10.4137/BIC.S11856.